Prediction of thrombocytopenia and bleeding risk in patients with von Willebrand disease type 2B was studied by performing the quantification of the von Willebrand factor from plasma samples in its GPIb-α binding conformation using the AU/VWFa-11 nanobody. This evidence concerns the gene GP1BA and von Willebrand disease type 2B.